0000000000082562

AUTHOR

Victoria Castel

showing 36 related works from this author

A New Mutation of the p53 Gene in Human Neuroblastoma, Not Correlated with N-myc Amplification

1999

N-myc gene amplification and/or loss of heterozygosity of chromosome 1 (LOH lp) are important criteria for prognosis and progression in human neuroblastoma (NB). Despite the high incidence of alterations of the p53 gene in human cancers, very few p53 mutations have been reported in NB. The objective of our study was to search for p53 mutations in NB and their correlation with N-myc amplification and clinical or pathologic parameters. We analyzed 14 selected cases of NB from the Spanish Protocol N-II-92. We found a missense mutation in codon 248 CGG to GGG (Arg/Gly) in one case of stage 4 NB with no N-myc amplification. Our results confirm the low incidence of p53 gene mutation in neuroblas…

0301 basic medicineChromosomeBiologyGene mutationmedicine.diseaseMolecular biologyPathology and Forensic MedicineLoss of heterozygosity03 medical and health sciences030104 developmental biology0302 clinical medicine030220 oncology & carcinogenesisNeuroblastomaGene duplicationmedicineCancer researchMissense mutationSurgeryAnatomyGeneN-MycInternational Journal of Surgical Pathology
researchProduct

Study of Proliferation and Apoptosis in Neuroblastoma. Their Relation with Other Prognostic Factors

2002

Abstract Background Our objective was to study the proliferation and apoptotic process in 111 cases of neuroblastoma (NB) and to seek their relationship with other prognostic factors and survival. Methods Immunohistochemistry following ABC peroxidase was carried out for PCNA, Ki-67, bcl-2, and p53 proteins. Apoptosis analysis was performed with in situ detection of chromosomal breakdown. Molecular detection of DNA ladders by electrophoresis and amplification of MYCN was studied with PCR and Southern blot. Statistical study was performed with Pearson χ 2 and Kruskal-Wallis tests and Cox regression. Results Our results indicate that proliferative factors PCNA and Ki-67 were correlated to each…

MaleIn situProgrammed cell deathTime FactorsMitosisApoptosisPolymerase Chain ReactionNeuroblastomachemistry.chemical_compoundProliferating Cell Nuclear AntigenNeuroblastomamedicineHumansChildSouthern blotbiologyInfant NewbornInfantCell DifferentiationDNAGeneral MedicinePrognosismedicine.diseaseImmunohistochemistryMolecular biologyProliferating cell nuclear antigenBlotting SouthernKi-67 AntigenProto-Oncogene Proteins c-bcl-2chemistryApoptosisChild PreschoolMultivariate Analysisbiology.proteinImmunohistochemistryFemaleTumor Suppressor Protein p53Cell DivisionDNAFollow-Up StudiesArchives of Medical Research
researchProduct

Alternative lengthening of telomeres--an enhanced chromosomal instability in aggressive non-MYCN amplified and telomere elongated neuroblastomas

2010

Telomere length alterations are known to cause genomic instability and influence clinical course in several tumor types, but have been little investigated in neuroblastoma (NB), one of the most common childhood tumors. In the present study, telomere-dependent chromosomal instability and telomere length were determined in six NB cell lines and fifty tumor biopsies. The alternative lengthening of telomeres (ALT) pathway was assayed by scoring ALT-associated promyelocytic leukemia (PML) bodies (APBs). We found a reduced probability of overall survival for tumors with increased telomere length compared to cases with reduced or unchanged telomere length. In non-MYCN amplified tumors, a reduced o…

AdultMaleGenome instabilityCancer ResearchBiologyNeuroblastomaYoung AdultCell Line TumorChromosomal InstabilityChromosome instabilityNeuroblastomaGeneticsmedicineHumansChildTelomeraseIn Situ Hybridization FluorescenceAnaphaseOncogene ProteinsN-Myc Proto-Oncogene ProteinOncogeneGene AmplificationInfant NewbornInfantNuclear ProteinsTelomeremedicine.diseaseMolecular biologyTelomereLeukemiaCell cultureChild PreschoolFemaleAnaphase
researchProduct

miR‐200c and phospho‐AKT as prognostic factors and mediators of osteosarcoma progression and lung metastasis

2016

Lung metastasis is the major cause of death in osteosarcoma patients. However, molecular mechanisms underlying this metastasis remain poorly understood. To identify key molecules related with pulmonary metastasis of pediatric osteosarcomas, we analyzed high-throughput miRNA expression in a cohort of 11 primary tumors and 15 lung metastases. Results were further validated with an independent cohort of 10 primary tumors and 6 metastases. In parallel, we performed immunohistochemical analysis of activated signaling pathways in 36 primary osteosarcomas. Only phospho-AKT associated with lower overall survival in primary tumors, supporting its role in osteosarcoma progression. CTNNB1 expression a…

0301 basic medicineOncologyMaleCancer ResearchmiR‐200cLung NeoplasmsCDH1MetastasisCohort Studies0302 clinical medicineCell MovementPhospho‐AKTPhosphorylationChildOsteosarcomabiologyGeneral MedicineArticlesCadherinsPrognosisPrimary tumorGene Expression Regulation Neoplasticmedicine.anatomical_structureLung metastasisOncology030220 oncology & carcinogenesisDisease ProgressionMolecular MedicineOsteosarcomaFemaleSignal Transductionmedicine.medical_specialtyAdolescentMesenchymal to epithelial transitionArticle03 medical and health sciencesYoung AdultAntigens CDInternal medicineCell Line TumormicroRNAGeneticsmedicineBiomarkers TumorHumansEpithelial–mesenchymal transitionCell ProliferationLungGene Expression ProfilingReproducibility of ResultsEpithelial CellsPediatric osteosarcomamedicine.diseaseSurvival AnalysisEnzyme ActivationMicroRNAs030104 developmental biologyTumor progressionbiology.proteinProto-Oncogene Proteins c-aktMolecular Oncology
researchProduct

Extracellular matrix composition defines an ultra-high-risk group of neuroblastoma within the high-risk patient cohort

2016

Background: Although survival for neuroblastoma patients has dramatically improved in recent years, a substantial number of children in the high-risk subgroup still die. Methods: We aimed to define a subgroup of ultra-high-risk patients from within the high-risk cohort. We used advanced morphometric approaches to quantify and characterise blood vessels, reticulin fibre networks, collagen type I bundles, elastic fibres and glycosaminoglycans in 102 high-risk neuroblastomas specimens. The Kaplan-Meier method was used to correlate the analysed elements with survival. Results: The organisation of blood vessels and reticulin fibres in neuroblastic tumours defined an ultra-high-risk patient subgr…

0301 basic medicineRiskCancer ResearchPathologymedicine.medical_specialtyblood vascularisationColorectal cancerKaplan-Meier EstimateRisk AssessmentCollagen Type IExtracellular matrix03 medical and health sciencesProstate cancerNeuroblastomaneuroblastoma0302 clinical medicineNeuroblastomamedicineHumansSurvival rateMolecular Diagnosticscollagen type I fibresbusiness.industryBrain Neoplasmsultra-high-risk neuroblastomaInfantExtracellular matrixelastic fibresmedicine.diseaseElastic TissuePrognosisSurvival RateReticulin030104 developmental biologymedicine.anatomical_structureOncologyglycosaminoglycans030220 oncology & carcinogenesisBlood Vesselsreticulin fibresBone marrowSkin cancerLiver cancerbusiness
researchProduct

Angiogenesis in neuroblastoma: relationship to survival and other prognostic factors in a cohort of neuroblastoma patients.

2000

PURPOSE: To study angiogenesis in neuroblastoma, using morphometric and computerized image analysis, and correlate the results with survival and other prognostic factors. PATIENTS AND METHODS: Sixty-nine patients from the Spanish Cooperative Study for Neuroblastoma were studied. Tumoral angiogenesis was studied using an avidin-biotin immunoperoxidase technique with an anti-CD34 antibody. Vascular parameters (VPs) were analyzed by a computerized system. Statistical analysis was also performed. RESULTS: Sixty-six samples had adequate tumoral tissue, and their tumoral vessels were counted. Endothelial cells were more prominent in pure neuroblastomas than in maturing and more mature tumors. VP…

Cancer ResearchPathologymedicine.medical_specialtyImmunoperoxidaseAngiogenesisbusiness.industrymedicine.diseaseNeovascularizationOncologyNeuroblastomamedicineImmunohistochemistryHistopathologyStage (cooking)medicine.symptombusinessSurvival rate
researchProduct

Determination of busulfan in human plasma using high-performance liquid chromatography with pre-column derivatization and fluorescence detection.

1999

A rapid, sensitive and reproducible high-performance liquid chromatographic assay for busulfan in human plasma was developed. After extraction of plasma samples with acetonitrile and methylene chloride, busulfan and the internal standard [1,5-bis(methanesulfonyloxy)pentane] were derivatized with 8-mercaptoquinoline to yield fluorescent compounds which were detected with a fluorescence detector equipped with filters of 360 nm (excitation) and 425 nm (emission). Calibration graphs showed a linear correlation (r>0.9990) over the concentration range of 20-2000 ng/ml. The recovery of busulfan from plasma standards was 70+/-5%. The detection and quantification limits for busulfan in plasma sample…

ChromatographyChemistryExtraction (chemistry)Reproducibility of ResultsGeneral ChemistryReference StandardsHigh-performance liquid chromatographyFluorescenceSensitivity and SpecificityFluorescence spectroscopyPentanechemistry.chemical_compoundSpectrometry FluorescenceCalibrationmedicineHumansDerivatizationQuantitative analysis (chemistry)Antineoplastic Agents AlkylatingBusulfanBusulfanChromatography High Pressure Liquidmedicine.drugJournal of chromatography. B, Biomedical sciences and applications
researchProduct

Next-Generation Sequencing Identifies Potential Actionable Targets in Paediatric Sarcomas

2021

Background: Bone and soft-tissue sarcomas represent 13% of all paediatric malignancies. International contributions to introduce next-generation sequencing (NGS) approaches into clinical application are currently developing. We present the results from the Precision Medicine program for children with sarcomas at a reference centre. Results: Samples of 70 paediatric sarcomas were processed for histopathological analysis, reverse transcriptase polymerase chain reaction (RT-PCR) and next-generation sequencing (NGS) with a consensus gene panel. Pathogenic alterations were reported and, if existing, targeted recommendations were translated to the clinic. Seventy paediatric patients with sarcomas…

0301 basic medicineOncologyCàncer en els infantsmedicine.medical_specialtyprecision medicinetargeted drugslcsh:MedicineMedicine (miscellaneous)Articlepaediatric sarcomasclinical translationDNA sequencinglaw.invention03 medical and health sciences0302 clinical medicinelawInternal medicineGene panelmedicineOssos MalaltiesPolymerase chain reactionPaediatric patientsBiological studiesbusiness.industrylcsh:RHistopathological analysisPrecision medicine030104 developmental biology030220 oncology & carcinogenesisCohortnext-generation sequencingbusinessJournal of Personalized Medicine
researchProduct

Neuropsychological rehabilitation in children with central nervous system tumors and irradiated leukemias

2012

Actualmente la intervención e investigación en psicooncología pediátrica se dirige hacia la evaluación de las consecuencias de la enfermedad y los efectos secundarios de los tratamientos, y a los factores predictivos tanto de desajustes como de aspectos adaptativos a la enfermedad del paciente y de su familia. Las tasas de curación alcanzadas en la actualidad, nos permiten contar con un número considerable de supervivientes de cáncer infantil, susceptibles de ser evaluados y poder determinar así las secuelas a largo plazo de la enfermedad y sus procedimientos terapéuticos. Además de incrementar considerablemente la supervivencia, también se ha mejorado la calidad de vida de los niños, media…

déficits neuropsicológicosPediatric cancer patientspsicopatologíaneuropsychological déficitsintervención psicológicalcsh:BF1-990Tumors en els infantspsychopathologypsychological intervention.lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogenslcsh:RC254-282neuropsychological assessmentClinical Psychologylcsh:PsychologyOncologyPacientes oncológicos pediátricosPsicooncología
researchProduct

Hypermethylation of apoptotic genes as independent prognostic factor in neuroblastoma disease

2010

Neuroblastoma (NB) is an embryonal tumour of neuroectodermal cells, and its prognosis is based on patient age at diagnosis, tumour stage and MYCN amplification, but it can also be classified according to their degree of methylation. Considering that epigenetic aberrations could influence patient survival, we studied the methylation status of a series of 17 genes functionally involved in different cellular pathways in patients with NB and their impact on survival. We studied 82 primary NB tumours and we used methylation-specific-PCR to perform the epigenetic analysis. We evaluated the putative association among the evidence of hypermethylation with the most important NB prognostic factors, a…

Regulation of gene expressionCancer ResearchMethylationDiseaseBiologymedicine.diseaseMolecular biologyNeuroblastomaDNA methylationmedicineCancer researchEpigeneticsAPAF1Molecular BiologyGeneMolecular Carcinogenesis
researchProduct

Two independent epigenetic biomarkers predict survival in neuroblastoma.

2015

Background Neuroblastoma (NB) is the most common extracranial pediatric solid tumor with a highly variable clinical course, ranging from spontaneous regression to life-threatening disease. Survival rates for high-risk NB patients remain disappointingly low despite multimodal treatment. Thus, there is an urgent clinical need for additional biomarkers to improve risk stratification, treatment management, and survival rates in children with aggressive NB. Results Using gene promoter methylation analysis in 48 neuroblastoma tumors with microarray technology, we found a strong association between survival and gene promoter hypermethylation (P = 0.036). Hypermethylation of 70 genes significantly …

Oncologymedicine.medical_specialtyCàncer en els infantsBioinformaticsCancer in childrenEpigenetic biomarkersNeuroblastomaNeuroblastomaInternal medicineGeneticsMedicineGene silencingEpigeneticsMolecular BiologyGenetics (clinical)business.industryRetinoblastomaResearchBiochemical markersPromoterMethylationmedicine.diseasePromoter methylationDNA methylationMarcadors bioquímicsGene chip analysisbusinessDevelopmental Biology
researchProduct

Comparative genetic study of intratumoral heterogenous MYCN amplified neuroblastoma versus aggressive genetic profile neuroblastic tumors.

2016

Intratumoral heterogeneous MYCN amplification (hetMNA) is an unusual event in neuroblastoma with unascertained biological and clinical implications. Diagnosis is based on the detection of MYCN amplification surrounded by non-amplified tumor cells by fluorescence in situ hybridization (FISH). To better define the genetic features of hetMNA tumors, we studied the Spanish cohort of neuroblastic tumors by FISH and single nucleotide polymorphism arrays. We compared hetMNA tumors with homogeneous MNA (homMNA) and nonMNA tumors with 11q deletion (nonMNA w11q-). Of 1091 primary tumors, 28 were hetMNA by FISH. Intratumoral heterogeneity of 1p, 2p, 11q and 17q was closely associated with hetMNA tumor…

Adult0301 basic medicineCancer ResearchCandidate geneAdolescentGene DosageSingle-nucleotide polymorphismBiologyPolymorphism Single NucleotideGene dosageGenetic profileCohort StudiesNeuroblastomaYoung Adult03 medical and health sciences0302 clinical medicineNeuroblastomaGeneticsmedicineHumansChildMolecular BiologyIn Situ Hybridization FluorescenceAgedAged 80 and overOncogene ProteinsGeneticsN-Myc Proto-Oncogene Proteinmedicine.diagnostic_testChromosomes Human Pair 11Nuclear ProteinsChromosomeMiddle Agedmedicine.diseaseNeuroblastic Tumor030104 developmental biologyChromosomes Human Pair 1Child PreschoolChromosomes Human Pair 2030220 oncology & carcinogenesisCancer researchChromosome DeletionChromosomes Human Pair 17Fluorescence in situ hybridization
researchProduct

Intra-Tumour Genetic Heterogeneity and Prognosis in High-Risk Neuroblastoma

2021

Simple Summary Neuroblastoma (NB) is the most common extra-cranial solid paediatric cancer and is responsible for 15% of childhood cancer deaths. Patients with NB are characterized by presenting a very heterogeneous clinic (inter-tumoural heterogeneity) and also both spatial and temporal intra-tumour heterogeneity (ITH) reflected in their genetic aberrations, which may be the consequence of the coexistence of different microenvironments within the tumour. Applying pangenomic techniques to detect genomic aberrations in different biopsies (solid and liquid) of high risk NB (HR-NB) we have detected spatial ITH in a surprisingly high percentage (almost 40%) of the studied cohort. Moreover, a po…

Solid tumourCancer Research<i>MYCN</i> amplificationGenetic heterogeneityMYCN amplificationNeoplasms. Tumors. Oncology. Including cancer and carcinogensGenomicsctDNABiologySNPaArticleOncologyMycn amplificationGenomic ProfileCancer researchgenomicssegmental chromosomal aberrationHigh risk neuroblastomaLiquid biopsytumour microenvironmentSurvival rateRC254-282Cancers
researchProduct

Age Dependency of the Prognostic Impact of Tumor Genomics in Localized Resectable MYCN-Nonamplified Neuroblastomas. Report From the SIOPEN Biology Gr…

2020

Purpose: For localized, resectable neuroblastoma without MYCN amplification, surgery only is recommended even if incomplete. However, it is not known whether the genomic background of these tumors may influence outcome. Patients and methods: Diagnostic samples were obtained from 317 tumors, International Neuroblastoma Staging System stages 1/2A/2B, from 3 cohorts: Localized Neuroblastoma European Study Group I/II and Children's Oncology Group. Genomic data were analyzed using multi- and pangenomic techniques and fluorescence in-situ hybridization in 2 age groups (cutoff age, 18 months) and were quality controlled by the International Society of Pediatric Oncology European Neuroblastoma (SIO…

OncologyCancer Researchmedicine.medical_specialtyGenomicsNeuroblastomaCogInternal medicineNeuroblastomaHumansMedicineProgression-free survivalSurvival rateNeoplasm StagingChromosome AberrationsClinical Trials as TopicN-Myc Proto-Oncogene ProteinValidation groupbusiness.industryChromosomes Human Pair 11Age FactorsGene AmplificationInfantORIGINAL REPORTSGenomicsPrognosismedicine.diseaseDiploidyProgression-Free SurvivalDoenças GenéticasSurvival RateOncologyPediatric OncologyChromosomes Human Pair 1Mycn amplificationNeoplasm stagingbusinessJournal of Clinical Oncology
researchProduct

Immunoproteomic studies on paediatric opsoclonus-myoclonus associated with neuroblastoma

2016

We aimed to identify new cell-membrane antigens implicated in opsoclonus-myoclonus with neuroblastoma. The sera of 3 out of 14 patients showed IgG electron-microscopy immunogold reactivity on SH-SY5Y neuroblastoma cells. Immunoprecipitation experiments using rat brain synaptosomes and SH-SY5Y cells led to the identification of: (1) thirty-one nuclear/cytoplasmic proteins (including antigens HuB, HuC); (2) seven neuronal membrane proteins, including the Shaw-potassium channel Kv3.3 (KCNC3), whose genetic disruption in mice causes ataxia and generalized muscle twitching. Although cell-based assays did not demonstrate direct antigenicity, our findings point to Shaw-related subfamily of the pot…

Central Nervous SystemMale0301 basic medicineAntigenicityDatabases FactualThymomaImmunoprecipitationKCTD7Cell Adhesion Molecules NeuronalImmunologyNerve Tissue ProteinsBiologyNeuroblastoma03 medical and health sciences0302 clinical medicineAntigenCell Line TumorNeuroblastomaOpsoclonus myoclonus syndromemedicineAnimalsHumansImmunology and AllergyRats WistarChildOpsoclonus-Myoclonus SyndromeBrain NeoplasmsMembrane ProteinsNuclear ProteinsImmunogold labellingmedicine.diseaseMolecular biologyRatsHEK293 Cells030104 developmental biologyShaw Potassium ChannelsNeurologyMembrane proteinEncephalitisFemaleNeurology (clinical)030217 neurology & neurosurgerySynaptosomesJournal of Neuroimmunology
researchProduct

Retinoblastoma and mosaic 13q deletion: a case report

2021

Abstract Background Patients with 13q-syndrome are at risk of retinoblastoma when the RB1 gene, located in the chromosomal band 13q14.2, is deleted. This syndrome is frequently associated with congenital malformations and developmental delay, although these signs could be mild. Mosaic 13q-deletion patients have been previously reported in the literature; their phenotype is variable, and they may not be recognized. Case presentation Retinoblastoma diagnosed in a child with 13q-mosaicism confirmed in blood, oral mucosa, healthy retina and retinoblastoma. A second RB1 hit is present exclusively in the retinoblastoma sample (RB1 c.958C&gt;T p.Arg320Ter). Other detected molecular events in retin…

medicine.medical_specialtyPathology13q-syndromeClinodactylyCitogenèticaCase ReportPhysical examinationMalignancyGenètica molecularCytogeneticsMolecular geneticsMedicineMolecular geneticsCàncermedicine.diagnostic_test13q deletion syndromeMosaicismbusiness.industryRetinoblastomaRetinoblastomaCytogeneticsRE1-994medicine.diseasePhenotypeeye diseasesOphthalmologymedicine.symptombusiness
researchProduct

Pharmacogenetics in Neuroblastoma: What Can Already Be Clinically Implemented and What Is Coming Next?

2021

Pharmacogenetics is one of the cornerstones of Personalized Precision Medicine that needs to be implemented in the routine of our patients’ clinical management in order to tailor their therapies as much as possible, with the aim of maximizing efficacy and minimizing toxicity. This is of great importance, especially in pediatric cancer and even more in complex malignancies such as neuroblastoma, where the rates of therapeutic success are still below those of many other types of tumors. The studies are mainly focused on germline genetic variants and in the present review, state of the art is presented: which are the variants that have a level of evidence high enough to be implemented in the c…

medicine.medical_specialtyQH301-705.5Antineoplastic AgentsReviewchemotherapyPediatricsCatalysisInorganic ChemistryNeuroblastomadrug labelQuimioteràpiamedicineHumansMedical physicsBiology (General)Precision MedicinePhysical and Theoretical Chemistryclinical implementation guidelinesQD1-999SNP (single nucleotide polymorphism)Molecular BiologySpectroscopybusiness.industryOrganic ChemistryGenetic variantsGeneral MedicineEvidence-based medicinePrecision medicinePediatric cancerComputer Science ApplicationsChemistryPharmacogeneticsFarmacogenèticabusinessPharmacogenetics
researchProduct

A stiff extracellular matrix is associated with malignancy in peripheral neuroblastic tumors

2017

Purpose and objective Improved prognosis for patients with peripheral neuroblastic tumors (PNB) depends on enhanced pretreatment risk stratification combined with research into new therapeutic targets. This study investigated the potential contribution of extracellular matrix (ECM) elements toward this endeavor. Methods We characterized certain elements such as reticulin fibers, collagen type I fibers, and elastic fibers by digital pathology in almost 400 untreated PNB. Results A reticular and poorly porous ECM was identified in neuroblastomas (NBs) from patients with clinical and biological features associated with poor prognosis compared with a loose and permeable matrix found in NBs of t…

0301 basic medicineReticular fiberPathologymedicine.medical_specialtybusiness.industryHematologyMatrix (biology)Malignancymedicine.diseaseNeuroblastic TumorPeripheralExtracellular matrix03 medical and health sciences030104 developmental biology0302 clinical medicineOncology030220 oncology & carcinogenesisNeuroblastomaPediatrics Perinatology and Child HealthReticular connective tissuemedicinebusinessPediatric Blood &amp; Cancer
researchProduct

Neuroblastoma after Childhood: Prognostic Relevance of Segmental Chromosome Aberrations, ATRX Protein Status, and Immune Cell Infiltration

2014

AbstractNeuroblastoma (NB) is a common malignancy in children but rarely occurs during adolescence or adulthood. This subgroup is characterized by an indolent disease course, almost uniformly fatal, yet little is known about the biologic characteristics. The aim of this study was to identify differential features regarding DNA copy number alterations, α-thalassemia/mental retardation syndrome X-linked (ATRX) protein expression, and the presence of tumor-associated inflammatory cells. Thirty-one NB patients older than 10 years who were included in the Spanish NB Registry were considered for the current study; seven young and middle-aged adult patients (range 18-60 years) formed part of the c…

MaleCancer ResearchHet heterogeneousGene ExpressionNeuroblastomaImmunophenotypingRegistriesYoung adultNeoplasm MetastasisMLPA multiplex ligation probe amplificationChildIn Situ Hybridization FluorescenceNuclear ProteinsMiddle AgedAYA adolescent and young adultsPrognosislcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensNCA numerical chromosome aberrationImmunohistochemistryFemaleSCA segmental chromosome aberrationIHC immunohistochemistryNB neuroblastomaAdultX-linked Nuclear ProteinAdolescentaSNP single nucleotide polymorphism arrayBiologyMalignancyChromosome aberrationPolymorphism Single Nucleotidelcsh:RC254-282ArticleImmunophenotypingYoung AdultLymphocytes Tumor-InfiltratingNeuroblastomacnLOH copy-neutral loss of heterozygositymedicineHumansHom homogeneousATRXNeoplasm StagingChromosome AberrationsDNA Helicasesmedicine.diseaseSpainMNNA MYCN not amplifiedCancer researchFSCA focal segmental chromosome aberrationCD8MNA MYCN amplifiedNeoplasia
researchProduct

Vascular patterns provide therapeutic targets in aggressive neuroblastic tumors

2016

// Irene Tadeo 1 , Gloria Bueno 2 , Ana P. Berbegall 1 , M. Milagro Fernandez-Carrobles 2 , Victoria Castel 3 , Marcial Garcia-Rojo 4 , Samuel Navarro 1 , Rosa Noguera 1 1 Pathology Department, Medical School, University of Valencia, INCLIVA, 46010 Valencia, Spain 2 VISILAB, E.T.S. Ingenieros Industriales, University of Castilla-La Mancha, 13071 Ciudad Real, Spain 3 Pediatric Oncology Unit, University and Polytechnic Hospital La Fe, 46026 Valencia, Spain 4 Department of Pathology, Hospital de Jerez de la Frontera, 11407 Jerez de la Frontera, Cadiz, Spain Correspondence to: Rosa Noguera Salva, e-mail: rnoguera@uv.es Keywords: extracellular matrix, blood vessels, capillaries, sinusoids, neuro…

0301 basic medicinePathologymedicine.medical_specialtyAngiogenesisextracellular matrixMalignancyMetastasisblood vesselsNeuroblastoma03 medical and health sciencesneuroblastoma0302 clinical medicinePediatric oncologyMedicineHumansTumor growthcapillariesChildsinusoidsTissue microarrayNeovascularization Pathologicbusiness.industrymedicine.diseaseNeuroblastic Tumor030104 developmental biologyOncology030220 oncology & carcinogenesisCohortDisease ProgressionbusinessResearch Paper
researchProduct

Genetic Instability and Intratumoral Heterogeneity in Neuroblastoma with MYCN Amplification Plus 11q Deletion

2013

Background/Aim Genetic analysis in neuroblastoma has identified the profound influence of MYCN amplification and 11q deletion in patients’ prognosis. These two features of high-risk neuroblastoma usually occur as mutually exclusive genetic markers, although in rare cases both are present in the same tumor. The purpose of this study was to characterize the genetic profile of these uncommon neuroblastomas harboring both these high-risk features. Methods We selected 18 neuroblastomas with MNA plus 11q loss detected by FISH. Chromosomal aberrations were analyzed using Multiplex Ligation-dependent Probe Amplification and Single Nucleotide Polymorphism array techniques. Results and Conclusion Thi…

Malelcsh:MedicineMutually exclusive eventsGenetic analysisPediatricsGenetic profileChromosome BreakpointsNeuroblastomaGene duplicationPathologylcsh:ScienceChildGeneticsOncogene ProteinsN-Myc Proto-Oncogene ProteinMultidisciplinaryNuclear ProteinsOncologyChild PreschoolCytogenetic AnalysisMedicineFemaleChromosome DeletionResearch ArticleGenetic MarkersBiologyPolymorphism Single NucleotideCytogeneticsDiagnostic MedicineNeuroblastomamedicineGeneticsCancer GeneticsHumansIn patientGenetic Predisposition to DiseaseneoplasmsBiologyClinical GeneticsChromosomes Human Pair 11lcsh:RGene AmplificationInfantmedicine.diseaseGenetic markerPediatric OncologyMycn amplificationCancer researchlcsh:QBiomarkersGeneral PathologyPLoS ONE
researchProduct

Predicting outcomes for children with neuroblastoma using a multigene-expression signature: a retrospective SIOPEN/COG/GPOH study

2009

Summary Background More accurate prognostic assessment of patients with neuroblastoma is required to better inform the choice of risk-related therapy. The aim of this study is to develop and validate a gene-expression signature to improve outcome prediction. Methods 59 genes were selected using an innovative data-mining strategy, and were profiled in the largest neuroblastoma patient series (n=579) to date using real-time quantitative PCR starting from only 20 ng of RNA. A multigene-expression signature was built using 30 training samples, tested on 313 test samples, and subsequently validated in a blind study on an independent set of 236 tumours. Findings The signature has a performance, s…

OncologyPediatricsmedicine.medical_specialtyMultivariate analysisbusiness.industryCase-control studyOdds ratiomedicine.diseaseBreast cancerOncologyNeuroblastomaInternal medicinemedicineStage (cooking)businessProspective cohort studySurvival analysisThe Lancet Oncology
researchProduct

Anaplastic lymphoma kinase expression in neuroblastomas and its relationship with genetic, prognostic, and predictive factors

2011

Gene DosageReceptor Protein-Tyrosine KinasesProtein-Tyrosine KinasesBiologyPrognosisPathology and Forensic MedicineCohort StudiesSurvival RateNeuroblastomaExpression (architecture)Cancer researchHumansAnaplastic lymphoma kinaseAnaplastic Lymphoma KinaseChromosome DeletionIn Situ Hybridization FluorescenceNeoplasm StagingHuman Pathology
researchProduct

Prognostic value of partial genetic instability in neuroblastoma with ≤50% neuroblastic cell content

2011

Piqueras M, Navarro S, Canete A, Castel V & Noguera R (2011) Histopathology59, 22–30 Prognostic value of partial genetic instability in neuroblastoma with ≤50% neuroblastic cell content Aims:  Better understanding of neuroblastoma genetics will improve with genome-wide techniques. However, performing these analyses in samples with <60% neuroblast cells is not adequate. We evaluated the utility of fluorescence in situ hybridization (FISH) on tissue microarrays (TMA) in detecting partial genetic instability (PGI), focusing on samples with ≤50% neuroblast cells. Methods and results:  Alterations of 11q and 17q were detected by FISH on 369 neuroblastoma samples in TMA. Status of the MYCN gene a…

medicine.medical_specialtyPathologyHistologyTissue microarraymedicine.diagnostic_testCellCancerAnatomical pathologyGeneral MedicineBiologymedicine.diseasePathology and Forensic Medicinemedicine.anatomical_structureNeuroblastGenetic markerNeuroblastomamedicinelipids (amino acids peptides and proteins)Fluorescence in situ hybridizationHistopathology
researchProduct

MYCN gain and MYCN amplification in a stage 4S neuroblastoma.

2003

Abstract Stage 4S neuroblastoma is a disease associated with spontaneous regression and good survival. We present a patient whose evolution has shown the variety and complexity of this disease in infants. Biologic factors, such as ploidy, MYCN copy number, loss of 1p36, and other chromosomal gains and losses were determined. A complex pattern of genetic abnormalities, such as near-diploidy, MYCN gain (2–4 copies per haploid genome) and imbalance/deletion of 1p36 was seen in the diagnostic sample. An extensive disseminated disease after a latent period of 26 months was associated with a special genetic evolution, such as tetraploidy, MYCN amplification (2:100–500 copies), 1p36 deletion, and …

Cancer ResearchAdrenal Gland NeoplasmsGenes mycDiseaseBiologymedicine.disease_causeNeuroblastomaFatal OutcomeNeuroblastomaGene duplicationGeneticsmedicineHumansneoplasmsMolecular BiologyNeoplasm StagingGeneticsMutationTransition (genetics)Gene AmplificationInfantmedicine.diseaseAneuploidyPrimary tumorChromosomes Human Pair 1Stage 4S NeuroblastomaCancer researchDisease ProgressionFemalePloidyChromosome DeletionChromosomes Human Pair 17Cancer genetics and cytogenetics
researchProduct

Expression of type I interferon receptor and its relation with other prognostic factors in human neuroblastoma.

1998

Expression of type I interferon receptor (IFN-R) has been found in several normal tissues and in malignant neoplasms, mainly those with epithelial differentiation. In order to analyze the immunohistochemical expression of type I IFN-R we studied 79 cases of neuroblastoma. Results of expression of type I IFN-R were statistically correlated with histopathology, stage, bcl-2 and PCNA expression, N-myc amplification and apoptosis. We found expression of type I IFN-R in 54/79 cases showing statistical correlation with bcl-2 expression (P=0.017) and favourable histopathology (P=0.015). The overexpression found in ganglion cells suggests that IFN-R could be involved in the pathway of neuroblastoma…

Cancer ResearchCellular differentiationmedicine.medical_treatmentGenes mycAlpha interferonApoptosisReceptor Interferon alpha-betaBiologyImmunoenzyme TechniquesNeuroblastomaProliferating Cell Nuclear AntigenNeuroblastomaGene expressionBiomarkers TumormedicineHumansChildInterferon alfaNeoplasm StagingReceptors InterferonOncogeneGene AmplificationInfantMembrane ProteinsCell DifferentiationGeneral MedicinePrognosismedicine.diseaseNeoplasm ProteinsCytokineProto-Oncogene Proteins c-bcl-2OncologySpainChild PreschoolCancer researchImmunohistochemistrymedicine.drugOncology Reports
researchProduct

Pharmacogenetics implementation in the clinics: information and guidelines for germline variants.

2018

The aim of this work was to supply an overview of the germline Pharmacogenetics that can be already implemented in the oncology clinical practice. An explanation of the three pillars considered necessary for determining which genetic polymorphisms should be used has been provided. These are PharmGKB single nucleotide polymorphism (SNP)-Drug Clinical Annotations with levels of evidence 1 or 2; the genetic information provided in the drug labels by the drug regulatory main agencies (Food and Drug Administration and European Medicines Agency, mainly); and the guidelines elaborated by international expert consortia (mainly Clinical Pharmacogenetics Implementation Consortium and Dutch Pharmacoge…

PharmGKBbusiness.industryMedicinebusinessBioinformaticsGermlinePharmacogeneticsCancer drug resistance (Alhambra, Calif.)
researchProduct

Imbalance between genomic gain and loss identifies high-risk neuroblastoma patients with worse outcomes

2021

Survival in high-risk neuroblastoma (HR-NB) patients remains poor despite multimodal treatment. We aimed to identify HR-NB patients with worse outcomes by analyzing the genomic instability derived from segmental chromosomal aberrations. We calculated 3 genomic instability indexes for primary tumor SNP array profiles from 127 HR-NB patients: (1) Copy number aberration burden (%gainslength+%losseslength), (2) copy number load (CNL) (%gainslength-%losseslength) and (3) net genomic load (NGL) (%gainsamount-%lossesamount). Tumors were classified according to positive or negative CNL and NGL genomic subtypes. The impact of the genomic instability indexes on overall survival (OS) was assessed with…

Male0301 basic medicineGenome instabilityOncologyCancer ResearchCopy number loadSNPa single nucleotide polymorphism arrayNeuroblastoma0302 clinical medicineHigh risk neuroblastomaSegmental chromosomal aberrationsHR high-riskCNA copy number aberrationTumor biologyCNL copy number loaddNGL decreased net genomic loadlcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensPrognosisPrimary tumornCNL negative copy number loadGI genomic instabilityHomogeneous030220 oncology & carcinogenesisMNA MYCN-amplificationFemaleHR-NB high-risk neuroblastomaNB neuroblastomaSNP arrayOriginal articlemedicine.medical_specialtyDNA Copy Number VariationsiNGL increased net genomic loadpCNL positive copy number loadhetMNA heterogeneous MYCN-amplificationlcsh:RC254-282Polymorphism Single NucleotideGenomic InstabilityUHR ultra-high-riskOS overall survivalNet genomic load03 medical and health sciencesSCA segmental chromosomal aberrationInternal medicineNeuroblastomamedicineHumansNGL net genomic loadGenetic Predisposition to DiseaseGenomic imbalanceGenetic Association StudiesEFS event-free survivalProportional Hazards ModelsChromosome AberrationsPloidieshomMNA homogeneous MYCN-amplificationProportional hazards modelbusiness.industryGene AmplificationGenetic Variationmedicine.diseasePatient Outcome AssessmentCopy number aberration burden030104 developmental biologybusinessNeoplasia
researchProduct

How to minimise the effect of tumour cell content in detection of aberrant genetic markers in neuroblastoma

2011

Background: Clinical heterogeneity reflects the complexity of genetic events associated with neuroblastoma (NB). To identify the status of all described genetic loci with possible prognostic interest, high-throughput approaches have been used, but only with tumour cell content >60%. In some tumours, necrotic, haemorrhagic and/or calcification areas influence the low amount of neuroblasts. We evaluated the effect of tumour cell content in the detection of relevant aberrant genetic markers (AGM) diagnosed by fluorescence in situ hybridisation (FISH) on tissue microarrays (TMA) in NB. Methods: Two hundred and thirty-three MYCN non-amplified primary NB included in 12 TMAs were analysed. Results…

Genetic MarkersMaleCancer ResearchPathologymedicine.medical_specialtyShort CommunicationCellBiologyneuroblastomaFISHaberrant genetic markersNeuroblastomatumour cell contentGene duplicationmedicineHumansNuclear proteinneoplasmsIn Situ Hybridization FluorescenceNeoplasm StagingOncogene ProteinsN-Myc Proto-Oncogene Proteinmedicine.diagnostic_testGene AmplificationChromosome MappingInfantNuclear Proteinsprognostic factorsCancerPrognosismedicine.diseaseSurvival Ratemedicine.anatomical_structureOncologyTissue Array AnalysisGenetic markerFemaleNeoplasm stagingFluorescence in situ hybridizationBritish Journal of Cancer
researchProduct

MTHFR and VDR Polymorphisms Improve the Prognostic Value of MYCN Status on Overall Survival in Neuroblastoma Patients

2020

Single nucleotide polymorphisms (SNPs) in Pharmacogenetics can play an important role in the outcomes of the chemotherapy treatment in Neuroblastoma, helping doctors maximize efficacy and minimize toxicity. Employing AgenaBioscience MassArray, 96 SNPs were genotyped in 95 patients looking for associations of SNP with response to induction therapy (RIT) and grade 3&ndash

Oncologymedicine.medical_specialtySNPSingle-nucleotide polymorphismLogistic regressionsurvivalCalcitriol receptorArticleCatalysislcsh:ChemistryInorganic ChemistryneuroblastomaInternal medicineNeuroblastomamedicineSNPPhysical and Theoretical Chemistrylcsh:QH301-705.5Molecular BiologySpectroscopypharmacogeneticsbiologybusiness.industryOrganic ChemistrytoxicityGeneral Medicinemedicine.diseaseComputer Science Applicationslcsh:Biology (General)lcsh:QD1-999Methylenetetrahydrofolate reductaseCohortbiology.proteinbusinessPharmacogeneticsInternational Journal of Molecular Sciences
researchProduct

Deletion of 11q in Neuroblastomas Drives Sensitivity to PARP Inhibition

2017

AbstractPurpose: Despite advances in multimodal therapy, neuroblastomas with hemizygous deletion in chromosome 11q (20%–30%) undergo consecutive recurrences with poor outcome. We hypothesized that patients with 11q-loss may share a druggable molecular target(s) that can be exploited for a precision medicine strategy to improve treatment outcome.Experimental Design: SNP arrays were combined with next-generation sequencing (NGS) to precisely define the deleted region in 17 primary 11q-loss neuroblastomas and identify allelic variants in genes relevant for neuroblastoma etiology. We assessed PARP inhibitor olaparib in combination with other chemotherapy medications using both in vitro and in v…

Male0301 basic medicineCancer ResearchDNA repairAntineoplastic AgentsAtaxia Telangiectasia Mutated ProteinsKaplan-Meier EstimatePoly(ADP-ribose) Polymerase InhibitorsBiologyModels BiologicalPolymorphism Single NucleotideImmunophenotypingOlaparibNeuroblastoma03 medical and health scienceschemistry.chemical_compound0302 clinical medicineRecurrenceCell Line TumorNeuroblastomaBiomarkers TumormedicineAnimalsHumansAllelesNeoplasm StagingCisplatinTemozolomideChromosomes Human Pair 11High-Throughput Nucleotide SequencingCancerDrug SynergismPrognosismedicine.diseaseXenograft Model Antitumor AssaysMolecular biologyDisease Models Animal030104 developmental biologyOncologychemistryDrug Resistance Neoplasm030220 oncology & carcinogenesisPARP inhibitorCancer researchFemaleChromosome DeletionHaploinsufficiencyBiomarkersmedicine.drugClinical Cancer Research
researchProduct

Intratumoral immunosuppression profiles in 11q-deleted neuroblastomas provide new potential therapeutic targets

2021

In this issue, Coronado et al. attempt to improve our understanding of the factors affecting the response to immunotherapy in a large subset of high‐risk neuroblastoma with hemizygous deletion of chromosome 11q. By using several computational approaches, the authors study potential transcriptional and post‐transcriptional pathways that may affect the response to immunotherapy and further be leveraged therapeutically in a biomarker‐directed fashion.

0301 basic medicineMaleCancer Researchmedicine.medical_treatmentRetinoic acidchemistry.chemical_compoundNeuroblastoma0302 clinical medicineTumor Microenvironment11q deletion anti-GD2 immunotherapy combination immunotherapy immune cell infiltration miRNAs neuroblastomaMedicineeducation.field_of_studyimmune cell infiltration11q deletionImmunosuppressionGeneral Medicinelcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensPatologiaNeoplasm ProteinsmicroRNAsSurvival Rateanti‐GD2 therapyOncology030220 oncology & carcinogenesiscombination immunotherapymiRNAsMolecular Medicineimmune checkpoint inhibitionFemaleImmunotherapyChromosome Deletionanti‐GD2 immunotherapyPopulationlcsh:RC254-282Disease-Free Survival03 medical and health sciencesImmune systemNeuroblastomaGeneticsImmune ToleranceHumanseducationRetrospective Studiesbusiness.industryChromosomes Human Pair 11Immunotherapymedicine.diseaseImmune checkpointBlockade030104 developmental biologychemistryCancer researchCommentarybusiness
researchProduct

Germline Predisposition to Pediatric Cancer, from Next Generation Sequencing to Medical Care

2021

Knowledge about genetic predisposition to pediatric cancer is constantly expanding. The categorization and clinical management of the best-known syndromes has been refined over the years. Meanwhile, new genes for pediatric cancer susceptibility are discovered every year. Our current work shares the results of genetically studying the germline of 170 pediatric patients diagnosed with cancer. Patients were prospectively recruited and studied using a custom panel, OncoNano V2. The well-categorized predisposing syndromes incidence was 9.4%. Likely pathogenic variants for predisposition to the patient’s tumor were identified in an additional 5.9% of cases. Additionally, a high number of pathogen…

Cancer ResearchCàncer en els infantsGenetic counselingBioinformaticsgermlineMedical careArticleDNA sequencingGermlineworking toolGenetic predispositionmedicinegenetic syndromeRC254-282genetic counselingbusiness.industryIncidence (epidemiology)Neoplasms. Tumors. Oncology. Including cancer and carcinogensCancerpediatric oncologymedicine.diseasePediatric cancerOncologyhereditary cancerbusinessgenetic predispositionGenèticaCancers
researchProduct

Analysis of biological prognostic factors using tissue microarrays in neuroblastic tumors

2009

Background Neuroblastic tumors (NT) are pediatric neoplasms with a heterogeneous genetic profile. They present genotypic alterations of prognostic value, the study of which is mandatory in designing therapeutic management. Tissue microarrays (TMA) from paraffin material allow the analysis of a large number of cases with minimal costs. The main purpose of the present study is to analyze specific genetic markers of neuroblastic tumors included in TMAs and determine their prognostic value. We compare the results obtained by different molecular techniques at different substrates to evaluate the feasibility of these assays. Procedure One hundred thirty-nine samples were included in four differen…

Genetic MarkersMalePathologymedicine.medical_specialtyDiseaseN-Myc Proto-Oncogene ProteinNeuroblastomaRisk FactorsGenotypeHumansMedicineStage (cooking)ChildRetrospective StudiesOncogene ProteinsN-Myc Proto-Oncogene ProteinTissue microarraybusiness.industryAge FactorsNuclear ProteinsCell DifferentiationRetrospective cohort studyHematologyPrognosisNeuroblastic TumorTreatment OutcomeOncologyTissue Array AnalysisGenetic markerMutationPediatrics Perinatology and Child HealthFemalebusinessPediatric Blood &amp; Cancer
researchProduct

Frequency and prognostic impact of ALK amplifications and mutations in the European Neuroblastoma Study Group (SIOPEN) high-risk neuroblastoma trial …

2021

Purpose: In neuroblastoma (NB), the ALK receptor tyrosine kinase can be constitutively activated through activating point mutations or genomic amplification. We studied ALK genetic alterations in high-risk (HR) patients on the HR-NBL1/SIOPEN trial to determine their frequency, correlation with clinical parameters, and prognostic impact. Materials and methods: Diagnostic tumor samples were available from 1,092 HR-NBL1/SIOPEN patients to determine ALK amplification status (n = 330), ALK mutational profile (n = 191), or both (n = 571). Results: Genomic ALK amplification (ALKa) was detected in 4.5% of cases (41 out of 901), all except one with MYCN amplification (MNA). ALKa was associated with …

0301 basic medicineCancer ResearchPrognostic ImpactAnaplastic Lymphoma Kinase/genetics; Child Preschool; Clinical Trials Phase III as Topic; Europe; Female; Follow-Up Studies; Gene Amplification; Humans; Infant; Male; Mutation Rate; N-Myc Proto-Oncogene Protein/genetics; Neuroblastoma/genetics; Prognosis; Randomized Controlled Trials as Topic; Risk Factors; Survival RateEuropean Neuroblastoma Study GroupSIOPENRELAPSE03 medical and health sciencesNeuroblastoma0302 clinical medicineText miningNeuroblastomahemic and lymphatic diseasesREVEALSMedicine and Health SciencesKINASEMedicineHigh risk neuroblastomaHETEROGENEITYCRIZOTINIBSEGMENTAL CHROMOSOMAL ALTERATIONSACTIVATING MUTATIONSPEDIATRIC-PATIENTSbusiness.industryALK receptor tyrosine kinasePoint mutationREARRANGEMENTSCHEMOTHERAPYmedicine.diseaseDoenças Genéticas030104 developmental biologyALKOncology030220 oncology & carcinogenesisCancer researchbusiness
researchProduct

Evaluación y rehabilitación neuropsicológica en oncología pediátrica.

2003

Objetivo. El presente trabajo tiene como objetivo el estudio de los efectos neuropsicológicos a largo plazo del cáncer infantil y sus tratamientos así como plantear propuestas para la rehabilitación cognitiva. Método. El método ha consistido en una revisión sistemática de los resultados en la literatura científica acerca de los efectos de la quimioterapia y la radioterapia sobre el SNC y en las funciones cognitivas y conductuales detectados a través de estudios de neuroimagen como calcificaciones y cambios en la sustancia blanca. Presentamos, además, el protocolo de evaluación neuropsicológica ejemplificado con un diagnóstico frecuente que presenta deterioro generalizado. Proponemos un prog…

Càncer en els infantslcsh:PsychologyNeuropsychologyCranial irradiationLate effectslcsh:BF1-990RehabilitationPediatric cancer survivorslcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogenslcsh:RC254-282
researchProduct